| Literature DB >> 27156192 |
Sudha Korwar1, Benjamin L Morris2, Hardik I Parikh1, Robert A Coover1, Tyler W Doughty3, Ian M Love2, Brendan J Hilbert4, William E Royer4, Glen E Kellogg1, Steven R Grossman5, Keith C Ellis6.
Abstract
C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD(+) as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50=0.24μM). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50=0.18μM) and 3-chloro- (IC50=0.17μM) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer.Entities:
Keywords: C-terminal Binding Protein; CtBP; Dehydrogenase; Hydroxyimine; MTOB; Oxime; Transcriptional co-repressor; Tumor suppressor gene
Mesh:
Substances:
Year: 2016 PMID: 27156192 PMCID: PMC4993153 DOI: 10.1016/j.bmc.2016.04.037
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641